Foghorn Therapeutics (NASDAQ: FHTX) has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today.
Mr. Maynard brings more than 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies.
In a statement, Adrian Gottschalk, president and CEO of Foghorn, commented, “I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline. Ryan is a seasoned biotech executive who brings proven financial and operational leadership. His experience scaling organizations will accelerate our mission to deliver novel therapies to patients.”
